FDA Clearance Tracker · K223402
HemosIL von Willebrand Factor Antigen
Last checked: Nov 19, 2026Latest source record: Dec 9, 2022 (this decision)Source: openFDAMethods & limitations
Decided
Dec 9, 2022
Substantially Equivalent
Time to decision
30 days
Received Nov 9, 2022. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Special
Device class
Class II
The decision
- FDA number
- K223402
- Device name
- HemosIL von Willebrand Factor Antigen
- Applicant
- Instrumentation Laboratory CO
- Applicant location
- Bedford, MA
- Received
- Nov 9, 2022
- Decided
- Dec 9, 2022
- Decision
- Substantially Equivalent
- Submission type
- Special
Device type
- Device class
- Class II
- Regulation
- 21 CFR 864.7290
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code GGP. The earliest in FDA's data is K761058, decided Feb 7, 1977.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K223402
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Instrumentation Laboratory CO
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K221359 · Decided Sep 29, 2023 · 506 days after receipt
Device type: System, Multipurpose For In Vitro Coagulation Studies (JPA) · Laboratory Medicine & Pathology
- HemosIL Liquid Anti-Xa510(k)
K223187 · Decided Jun 23, 2023 · 254 days after receipt
Device type: Anti-Factor Xa Activity Test System, Apixaban (QLU) · Laboratory Medicine & Pathology
- GEM Premier ChemSTAT510(k)
K223090 · Decided Jan 27, 2023 · 119 days after receipt
Device type: Glucose Oxidase, Glucose (CGA) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.